Which companies are Rznomics's closest peers?

The cockpit's peer set: Guangdong Vtr Bio-Tech (300381.SZ), Beijing Luzhu Biotechnology (2480.HK), Onconic Therapeutics (476060.KS), C4 Therapeutics (CCCC), Contineum Therapeutics (CTNM), PureTech Health (PRTC.L), Zura Bio (ZURA), Editas Medicine (EDIT).

Is Rznomics expensive compared with its peers?

On ev / sales it trades at 244.5× against a peer median of 5.7×, 4th most expensive of 16 in its peer set.

How has Rznomics stock performed?

Over six months to 6 Nov 2026 the shares returned -78.8% against -32.8% for the median peer.

← CockpitCompetitor Analysis › 476830.KS Rznomics Inc.Open in the cockpit ↗

Rznomics Inc.476830.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Momentum laggard 4

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$386M

US dollars, full cap

Free float

59%

of shares outstanding

$/day

$4.68M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-177.0 pp

WACC 5.5%

Hurdle

n/a

no reverse DCF

Close · KRW₩18,600

1D-9.3%

1W-12.7%

1M-34.3%

3M-41.0%

6M-78.8%

YTD-76.8%

1Yn/a

ATR %11.4%

52w lowhigh84.8% off high

What Rznomics does

No business profile yet.

Rznomics at a glance

Size Rznomics (476830.KS) is a South Korea Health Care company (Biotechnology) with a market value of $386M, the 403rd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩18,600 on 6 Nov 2026.

Performance Over six months the shares fell 78.8%, against -32.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue fell 71.7% over the last twelve months (peer median +2.8%); the operating margin is -1,440.1% (peer median -177.6%).

Valuation It trades at 244.5× enterprise value to sales against a peer median of 5.7× (4th most expensive of 16).

Capital Return on invested capital runs 177.0 points below its cost of capital (5.5% WACC).

Relative performance

Six months, rebased to 100: Rznomics against the median of its 20 peers (local-currency closes).

Rznomics financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₩2.00B	₩7.92B	₩0	₩144M	₩0
Revenue growth	—	—	-100%	—	—
Gross profit	n/a	n/a	-₩1.08B	-₩812M	-₩703M
EBITDA	-₩27.8B	-₩13.6B	-₩11.8B	-₩14.6B	-₩18.5B
Net income	-₩27.6B	-₩104B	-₩18.9B	-₩13.6B	-₩31.5B
Free cash flow	-₩23.5B	-₩10.9B	-₩11.5B	-₩14.8B	-₩15.1B
Capital expenditure	₩670M	₩121M	₩310M	₩507M	₩675M
Total debt	₩1.45B	₩1.19B	₩51.1B	₩21.6B	₩17.8B

Quarterly statements and history in the cockpit →

Rznomics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Rznomics is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rznomics is the large dot.

Rznomics competitors and peer comparison

How Rznomics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rznomics against its 20 peers (data as of 6 Nov 2026)
Measure	476830.KS	Peer median	Rank in peer set
1-month return	-34.3%	-12.1%	2nd lowest of 20
6-month return	-78.8%	-32.8%	lowest of 19
Distance from 52-week high	-84.8%	-53.8%	lowest of 20
Revenue growth (TTM)	-71.7%	+2.8%	2nd lowest of 16
Operating margin	-1,440.1%	-177.6%	6th lowest of 16
EV / Sales	244.5×	5.7×	4th most expensive of 16
ROIC minus cost of capital	-177.0 pp	-17.7 pp	2nd lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Rznomics 476830.KS	South Korea	$386M	-79%	-72%	-1,440%	244.5×	n/a	n/a
Guangdong Vtr Bio-Tech 300381.SZ	China	$384M	-23%	-4%	-4%	2.7×	n/a	n/a
Beijing Luzhu Biotechnology 2480.HK	Hong Kong	$390M	-33%	n/a	n/a	n/a	n/a	n/a
Onconic Therapeutics 476060.KS	South Korea	$391M	-45%	+179%	21%	5.7×	2.0%	+725.2%
C4 Therapeutics CCCC	United States	$381M	+5%	+2%	-288%	5.3×	n/a	n/a
Contineum Therapeutics CTNM	United States	$381M	-34%	n/a	n/a	n/a	n/a	n/a
PureTech Health PRTC.L	United Kingdom	$394M	-8%	-4%	-1,617%	28.4×	n/a	n/a
Zura Bio ZURA	United States	$394M	-15%	n/a	n/a	n/a	n/a	n/a
Editas Medicine EDIT	United States	$395M	-17%	+21%	-178%	5.4×	n/a	n/a
AgomAb Therapeutics NV ADR AGMB	United States	$376M	-37%	n/a	n/a	n/a	n/a	n/a
G2GBIO 456160.KS	South Korea	$370M	-65%	-45%	-2,884%	775.0×	n/a	n/a
Altimmune ALT	United States	$405M	-33%	+55%	-320,726%	3,686.9×	n/a	n/a
Edding Genor 6998.HK	Hong Kong	$408M	-45%	+1,418%	26%	0.9×	-15.8%	+197.3%
Surrozen SRZN	United States	$364M	-35%	-9%	-385%	23.3×	n/a	n/a
Prothena PRTA	United States	$409M	-26%	+427%	-110%	2.4×	n/a	n/a
Lyell Immunopharma LYEL	United States	$364M	-23%	-55%	-729,281%	7,653.4×	n/a	n/a
Beijing Kawin Technology Share-Holding 688687.SS	China	$410M	-19%	+3%	0%	1.6×	43.0%	+8.9%
Zhejiang Laifual Drive 3952.HK	Hong Kong	$363M	n/a	+142%	-11%	7.1×	n/a	n/a
Aspen Neuroscience ASPE	United States	$362M	n/a	n/a	n/a	n/a	n/a	n/a
CorMedix CRMD	United States	$415M	-33%	+280%	47%	0.7×	n/a	n/a
Allogene Therapeutics ALLO	United States	$359M	-54%	-100%	-3,886%	22.8×	n/a	n/a

Questions

Which companies are Rznomics's closest peers?: The cockpit's peer set: Guangdong Vtr Bio-Tech (300381.SZ), Beijing Luzhu Biotechnology (2480.HK), Onconic Therapeutics (476060.KS), C4 Therapeutics (CCCC), Contineum Therapeutics (CTNM), PureTech Health (PRTC.L), Zura Bio (ZURA), Editas Medicine (EDIT).
Is Rznomics expensive compared with its peers?: On ev / sales it trades at 244.5× against a peer median of 5.7×, 4th most expensive of 16 in its peer set.
How has Rznomics stock performed?: Over six months to 6 Nov 2026 the shares returned -78.8% against -32.8% for the median peer.